July 30, 2026

#diabetes — Thursday, July 30, 2026 (2 items)

hot top new

0		💬 0	Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. (linkinghub.elsevier.com)	Mora P … Rosenstock J The Lancet 2026-07-30	#diabetes #clinical trial #pharmacology #therapeutics
0		💬 0	Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. (linkinghub.elsevier.com)	Mora P … Rosenstock J The Lancet 2026-07-30	#diabetes #clinical trial #pharmacology #therapeutics